Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ongoing, recruiting
Participants planned
8
Countries
1
Sites
1
Healthy volunteers
Key facts
- Sponsor
- Farmalider S.A.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male
- Therapeutic area
- Not possible to specify
- Trial duration
- 7 May 2026 → ongoing
- Decision date (initial)
- 2026-04-29
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Healthy volunteers
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Farmalider S.A.
- Sponsor organisation
- Farmalider S.A.
- Address
- Calle De La Granja 1 Planta 3
- City
- Alcobendas
- Postcode
- 28108
- Country
- Spain
Scientific contact point
- Organisation
- Farmalider S.A.
- Contact name
- Carlos Calandria
Public contact point
- Organisation
- Farmalider S.A.
- Contact name
- Carlos Calandria
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Spain | Ongoing, recruiting | 8 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Spain | 2026-05-07 | 2026-05-11 |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-03-17 | Spain | Acceptable 2026-04-28
|
2026-04-29 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2026-04-30 | Spain | Acceptable 2026-04-28
|
2026-04-30 |